A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study

References

• World Health Organization (WHO)Burden of COPD Available from: http://www.who.int/respiratory/copd/burden/en/Accessed October 29, 2014
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD 2014)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2014) Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014.pdfAccessed November 13, 2014
   Google Scholar
• BuistASMcBurnieMAVollmerWMInternational variation in the prevalence of COPD (the BOLD Study): a population-based prevalence studyLancet2007370958974175017765523
   PubMed Web of Science ®Google Scholar
• TageldinMANaftiSKhanJADistribution of COPD-related symptoms in the Middle East and North Africa: results of the BREATHE studyRespir Med2012106Suppl 2S25S3223290701
   PubMed Web of Science ®Google Scholar
• Regional COPD Working GroupCOPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation modelRespirology20038219219812753535
   PubMed Web of Science ®Google Scholar
• IdolorLFDE GuiaTSFranciscoNABurden of obstructive lung disease in a rural setting in the PhilippinesRespirology20111671111111821801277
   PubMed Web of Science ®Google Scholar
• McKayAJMaheshPAFordhamJZMajeedAPrevalence of COPD in India: a systematic reviewPrim Care Respir J201221331332122790612
   PubMedGoogle Scholar
• UzaslanEMahboubBBejiMThe burden of chronic obstructive pulmonary disease in the Middle East and North Africa: results of the BREATHE studyRespir Med2012106Suppl 2S45S5923290704
   PubMed Web of Science ®Google Scholar
• Onbrez Breezhaler^® 150 and 300 microgram inhalation powder, hard capsules [UK Summary of Product Characteristics] Updated October 23, 2014Surrey, UKNovartis Pharmaceuticals UK Ltd Available from: http://www.medicines.org.uk/EMC/medicine/23260/SPC/Onbrez+Breezhaler+150+and+300+microgram+inhalation+powder%2c+hard+capsules/Accessed October 29, 2014
   Google Scholar
• PavkovRMuellerSFiebichKCharacteristics of a capsule based dry powder inhaler for the delivery of indacaterolCurr Med Res Opin201026112527253320843166
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
   PubMed Web of Science ®Google Scholar
• KornSKerwinEAtisSIndacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week studyRespir Med2011105571972621367594
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLötvallJOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• DahlRChungKFBuhlREfficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
   PubMed Web of Science ®Google Scholar
• BuhlRDunnLJDisdierCBlinded 12-week comparison of once-daily indacaterol and tiotropium in COPDEur Respir J201138479780321622587
   PubMed Web of Science ®Google Scholar
• ChapmanKRRennardSIDograALong-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled studyChest20111401687521349928
   PubMed Web of Science ®Google Scholar
• DonohueJFSinghDKornmannOLawrenceDLassenCKramerBSafety of indacaterol in the treatment of patients with COPDInt J Chron Obstruct Pulmon Dis2011647749222003293
   PubMed Web of Science ®Google Scholar
• IdreesMKoniskiMLTarightSManagement of chronic obstructive pulmonary disease in the Middle East and North Africa: results of the BREATHE studyRespir Med2012106Suppl 2S33S4423290703
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD 2009)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2009) Available from: http://www.goldcopd.comAccessed October 29, 2014
   Google Scholar
• KocksJWKerstjensHASnijdersSLHealth status in routine clinical practice: validity of the clinical COPD questionnaire at the individual patient levelHealth Qual Life Outcomes2010813521080960
   PubMed Web of Science ®Google Scholar
• van der MolenTWillemseBWSchokkerSten HackenNHPostmaDSJuniperEFDevelopment, validity and responsiveness of the Clinical COPD QuestionnaireHealth Qual Life Outcomes200311312773199
   PubMedGoogle Scholar
• KocksJWTuinengaMGUilSMvan den BergJWStåhlEvan der MolenTHealth status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaireRespir Res200676216603063
   PubMed Web of Science ®Google Scholar
• StällbergBNokelaMEhrsPOHjemdalPJonssonEWValidation of the clinical COPD Questionnaire (CCQ) in primary careHealth Qual Life Outcomes200972619320988
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• KocksJWvan den BergJWKerstjensHADay-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2013827328623766644
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• ChapmanKRFogartyCMPeckittCDelivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPDInt J Chron Obstruct Pulmon Dis2011635336321760722
   PubMed Web of Science ®Google Scholar
• MolimardMColthorpePInhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitionersJ Aerosol Med Pulm Drug Deliv201528321922825265316
   PubMed Web of Science ®Google Scholar
• HerlandKAkselsenJPSkjønsbergOHBjermerLHow representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease?Respir Med2005991111915672843
   PubMed Web of Science ®Google Scholar
• SaturniSBelliniFBraidoFRandomized controlled trials and real life studies. Approaches and methodologies: a clinical point of viewPulm Pharmacol Ther201427212913824468677
   PubMed Web of Science ®Google Scholar
• OhnoTWadaSHanadaSSawaguchiHMurakiMTohdaYEfficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferencesInt J Chron Obstruct Pulmon Dis2014910711424489464
   PubMed Web of Science ®Google Scholar
• SinghMPIndacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohortInt J Chron Obstruct Pulmon Dis2013861361924353411
   PubMed Web of Science ®Google Scholar
• HatajiONaitoMItoKWatanabeFGabazzaECTaguchiOIndacaterol improves daily physical activity in patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis201381523293514
   PubMed Web of Science ®Google Scholar